-
6/12/2024
AstraZeneca’s FARXIGA®has been approved by the美国Food and Drug Administration to improve glycemic control in pediatric patients with type-2diabetes aged10years and older。
-
6/10/2024
AstraZeneca’s supplemental New Drug Application for TAGRISSO®has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable，Stage III epidermal growth factor receptor-mutated non-small cell lung cancer after chemoradiotherapy。
-
6/5/2024
The Department of Health–Abu Dhabi，the regulator of the healthcare sector in the Emirate，signed a Memorandum of Understanding with AstraZeneca during BIO International Convention 2024 to establish a world-class Rare Diseases Centre of Excellence in Abu Dhabi。
-
6/2/2024
定位results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO®demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival for patients with unresectable，Stage III epidermal growth factor receptor-mutated non-small cell lung cancer whose tumors have exon19 deletions or exon21 mutations，after chemoradiotherapy compared to placebo after CRT。
-
6/2/2024
定位results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI®demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overal survival and progression-free survival compared to placebo for patients with limited-stall survival procell ollowing standard-of-care concurrent chemoradiotherapy。
-
6/2/2024
Detailed positive results from the DESTINY-Breast06 Phase III trial showed that ENHERTU®demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in patients with HR-positive，HER2-low metatic breast cancer and the overall trial population following one or more lines of endocrine therapy。
-
5/31/2024
AstraZeneca is pleased to announce that Traqap™in combination with fulvestrant is now available in Canada for the treatment of adult female patients with hormone receptor-positive，human epidermal growth factor receptor2-negative locally advanced or metastatic breast cancer with one or more PIK3CA，AKT1or PTEN alterations following progression on at least one endocrine-based regimen in the metatic setting or recurrence on or within12months of completing adjuvantthery。
-
5/29/2024
Fusion Pharmaceuticals Inc.announced that at a special meeting of its shareholders，held virtually earlier today， the Shareholders voted in favour of the resolution to approve the previously announced plan of arrangement with a wholly-owned subsidiary of AstraZeneca under the Canada Business Corporations Act pursuant to which AstraZeneca will acquire all of the issued and outstanding shares of Fusion。
-
As AstraZeneca looks to climb toward the top of biopharma companies by revenue by the end of the decade，smaller companies are looking to join the ranks of the unofficial Big Pharma club。
-
AstraZeneca on Wednesday unveiled Phase I results for its PCSK9inhibitor，acquired from Dogma Therapeutics in 2020，which when combined with a statin reduced LDL-C levels in patients with high“bad”cholesterol。
-
AstraZeneca and Daiichi Sankyo’sinvestigational antibody-drug conjugate Dato-DXd failed to significantly improve overall survival in non-small cell lung cancer patients versus docetaxel。
-
5/27/2024
高电平overall survival results from the TROPION-Lung01 Phase III trial，which previously met the dual primary endpoint of progression-free survival， numerically favoured datopotamab deruxtecan compared to docetaxel in the overall trial population of patients with locally advanced or metastatic non-small cell lung cancer treated with at least one prior line of therapy。
-
5/22/2024
AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading portfolio and pipeline at the American Society of Clinical Oncology Annual Meeting，May31 to June42024。
-
5/21/2024
AstraZeneca revealed its bold ambition to deliver$80billion in Total Revenue by2030，up from$45.8billion in 2023。
-
AstraZeneca on Tuesday laid out an ambitious plan to boost growth in its existing oncology，biopharma and rare disease portfolios，as well as launch20new medicines before the end of the decade。
-
Pfizer’s Wyeth unit notched a legal victory over AstraZeneca on Friday as a federal jury found the British-Swedish company violated two key patents in developing and marketing its lung cancer drug Tagrisso。
-
To support its growing antibody-drug conjugate portfolio，AstraZeneca on Monday said it is investing$1.5 billion in a Singapore production site that will include all steps of the ADC manufacturing process。
-
5/19/2024
The Phase Iia COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease with a broad range of blood eosinophil counts and irrespective of emphysema，chronic bronchitis or smoking status。
-
5/15/2024
AlzeCure Pharma AB announced that Professor Jan Lundberg has been elected as annew board member at the company's annual general meeting in 2024。
-
5/8/2024
Premier， Inc.is excited to announce a strategic partnership with AstraZeneca called Uncover CKD-Care Collective aiming to identify patients with undignosed clinical chronic kidney disease；raise awareness of undiagnosed CKD among healthcare providers；and inform U.S.health systems that want and providers gies for CKD diagnosis，treatment and management。
